SCHEMBL3973975

SCHEMBL3973975

CCN(CC)CCCC(C)Nc1nc(-c2ccc(Br)cc2)nc2cc(OC)c(OC)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 5/20 0.60
PGK1 P00558 1/20 0.52
CSK P41240 1/20 0.51
BTK Q06187 1/20 0.51
ERBB4 Q15303 1/20 0.51
CAMK1G Q96NX5 1/20 0.51
SLC2A1 P11166 1/20 0.51
MELK Q14680 1/20 0.46
APP P05067 2/20 0.44
USP2 O75604 2/20 0.44
TP53 P04637 2/20 0.44
CYP3A4 P08684 2/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
HBB P68871 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 1/20 0.44
PRNP P04156 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5260533 0.91 CCR4 (0.58) CCR4PGK1CSKBTKERBB4
SCHEMBL3971090 0.84 CCR4 (0.62) CCR4BTKERBB4SLC2A1MELK
SCHEMBL3974464 0.84 POLB (0.57) SLC2A1KDM1AKDM4EALDH1A1POLB
SCHEMBL3974794 0.83 CCR4 (0.61) CCR4CSKBTKERBB4CAMK1G
SCHEMBL3977037 0.82 POLB (0.53) SLC2A1KDM1AKDM4EALDH1A1POLB
SCHEMBL3975275 0.77 CCR4 (0.63) CCR4CSKBTKERBB4CAMK1G
SCHEMBL3971151 0.75 CCR4 (0.68) CCR4CSKBTKERBB4CAMK1G
SCHEMBL6673288 0.74 CCR4 (0.68) CCR4CSKBTKERBB4CAMK1G
SCHEMBL3974654 0.74 ACP1 (0.54) SLC2A1KDM1AKDM4EMEN1ALDH1A1
SCHEMBL3973396 0.73 TLR9 (0.56) SLC2A1KDM1AKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 CCR4 3890/4885PGK1 2021/4885CSK 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.